REVIEW
|
doi:10.20944/preprints202204.0202.v1
Subject:
Medicine And Pharmacology,
Endocrinology And Metabolism
Keywords:
Metabolic syndrome; SGLT2 inhibitors; Dapagliflozin; Empagliflozin; Canagliflozin; Translational modeling
Online: 21 April 2022 (10:12:04 CEST)